

	Placebo	Natalizumab	OR (a)	Two-sided 90% Confidence Interval	One-sided p-value (b)
Number of subjects in the MITT population	82	77			
Day 90	78 (100)	72 (100)	1.15	[0.71, 1.86]	0.243
0	4 (5)	8 (11)			
1	12 (15)	10 (14)			
2	12 (15)	10 (14)			
3	15 (19)	13 (18)			
4	14 (18)	11 (15)			
5	8 (10)	6 (8)			
6	13 (17)	14 (19)			

Note: The MITT population is defined as all subjects who were randomized and have received the entire infusion of study treatment.

(a)Odds ratio from a proportional-odds logistic regression model assuming a common odds ratio across all cut points of the mRS score. Covariates include baseline DWI volume (< median vs >= median), treatment time window, location of stroke abnormality (cortical/subcortical), and tPA use (yes/no).

(b)P-value based on Van Elteren's test, adjusting for baseline DWI volume (< median vs >= median), treatment time window, location of stroke abnormality (cortical/subcortical), and tPA use (yes/no).